Balance Kviðskilunarlausn 2,3 % アイスランド - アイスランド語 - LYFJASTOFNUN (Icelandic Medicines Agency)

balance kviðskilunarlausn 2,3 %

fresenius medical care deutschland gmbh - natrii chloridum; calcii chloridum; magnesii chloridum; glucosum; natrii lactas - kviðskilunarlausn - 2,3 %

Balance Kviðskilunarlausn 4,25 % アイスランド - アイスランド語 - LYFJASTOFNUN (Icelandic Medicines Agency)

balance kviðskilunarlausn 4,25 %

fresenius medical care deutschland gmbh - natrii chloridum; calcii chloridum; magnesii chloridum; glucosum; natrii lactas - kviðskilunarlausn - 4,25 %

Ciprofloxacin Navamedic (Ciprofloxacin Villerton) Innrennslislyf, lausn 2 mg/ml アイスランド - アイスランド語 - LYFJASTOFNUN (Icelandic Medicines Agency)

ciprofloxacin navamedic (ciprofloxacin villerton) innrennslislyf, lausn 2 mg/ml

navamedic asa - ciprofloxacinum laktat - innrennslislyf, lausn - 2 mg/ml

Doxorubicin medac Innrennslislyf, lausn 2 mg/ml アイスランド - アイスランド語 - LYFJASTOFNUN (Icelandic Medicines Agency)

doxorubicin medac innrennslislyf, lausn 2 mg/ml

medac gesellschaft für klinische spezialpräparate gmbh - doxorubicinum hýdróklóríð - innrennslislyf, lausn - 2 mg/ml

Marcain Stungulyf, lausn 2,5 mg/ml アイスランド - アイスランド語 - LYFJASTOFNUN (Icelandic Medicines Agency)

marcain stungulyf, lausn 2,5 mg/ml

aspen pharma trading limited - bupivacainum hýdróklóríð - stungulyf, lausn - 2,5 mg/ml

Marcain Stungulyf, lausn 5 mg/ml アイスランド - アイスランド語 - LYFJASTOFNUN (Icelandic Medicines Agency)

marcain stungulyf, lausn 5 mg/ml

aspen pharma trading limited - bupivacainum hýdróklóríð - stungulyf, lausn - 5 mg/ml

Sobril Tafla 10 mg アイスランド - アイスランド語 - LYFJASTOFNUN (Icelandic Medicines Agency)

sobril tafla 10 mg

pfizer aps - oxazepamum inn - tafla - 10 mg

Sobril Tafla 15 mg アイスランド - アイスランド語 - LYFJASTOFNUN (Icelandic Medicines Agency)

sobril tafla 15 mg

pfizer aps - oxazepamum inn - tafla - 15 mg

Sobril Tafla 25 mg アイスランド - アイスランド語 - LYFJASTOFNUN (Icelandic Medicines Agency)

sobril tafla 25 mg

pfizer aps - oxazepamum inn - tafla - 25 mg

Lytgobi 欧州連合 - アイスランド語 - EMA (European Medicines Agency)

lytgobi

taiho pharma netherlands b.v. - futibatinib - cholangiocarcinoma - antineoplastic lyfjum - lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.